Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of a Prototype Hand Held Hybrid Gamma Camera (BIVISTA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03920371
Recruitment Status : Completed
First Posted : April 18, 2019
Last Update Posted : April 18, 2019
Sponsor:
Collaborators:
Nottingham University Hospitals NHS Trust
University of Nottingham
Information provided by (Responsible Party):
University of Leicester

Brief Summary:
The aim of the project is to undertake clinical development of a hybrid compact gamma camera that combines gamma ray and optical imaging. It is an extension of the previous pilot study using a newly developed handheld hybrid compact gamma camera in clinical arena.

Condition or disease Intervention/treatment Phase
Tumour Other: gamma camera imaging Not Applicable

Detailed Description:

This is a single visit study involving patients who have been referred to the Nuclear Medicine Clinic at Nottingham University Hospitals as part of a standard diagnostic test. Each patient's participation will be approximately 30 minutes and not normally longer than one hour. The study will run for 11 months commencing February 2017 and ceasing at the end of December 2017.

As part of their routine care, patients will be sent a letter booking their diagnostic test through a Nuclear Medicine Clinic. Once they have confirmed that they will be attending this diagnostic test, one of the clinical study team trained to take consent will contact the patient by phone. At this point they will be informed of the reason for the study, why they have been approached and the study schedule. If they express interest in participating they will then be sent a copy of the patient informed consent forms. They will be given a minimum of 24 hours before formally signing consent at the study site immediately before participating.

Study plan:

Following the administration of the routine radiopharmaceutical and the standard wait before clinical diagnostic imaging, the patient will have research images acquired using the hybrid prototype gamma camera. All research images will be anonymised and the additional imaging performed as part of this study will fit in with the patient and the diagnostic test schedules. Should the patient wish to stop at any point, the research study procedure will be terminated. Once these images have been acquired then the patient will go home or proceed with the requirements of their diagnostic test. 75 participants will be recruited for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 75 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Extended Pilot Evaluation of a Prototype Hand Held Hybrid Gamma Camera
Actual Study Start Date : June 13, 2017
Actual Primary Completion Date : September 10, 2018
Actual Study Completion Date : September 10, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: gamma camera imaging
hand held camera
Other: gamma camera imaging
Following the administration of the routine radiopharmaceutical and the standard wait before clinical diagnostic imaging, additional research gamma camera imaging is carried out




Primary Outcome Measures :
  1. Agreement of the visualisation of radiopharmaceutical uptake between the hybrid gamma camera and the standard clinical gamma camera for the sites investigated. [ Time Frame: 1 year ]

    The subjective assessment of scintigraphic images obtained using the hybrid camera under test and the standard clinical gamma camera.

    The image data will be didvdiid into the different exam types and scored using a 3 point scale.



Secondary Outcome Measures :
  1. The clinical optimisation of the hybrid gamma camera image display [ Time Frame: 1 year ]
    Following subjective assessment of the recorded images the data set will be reviewed by experienced observers and the display fusion will be modified to obtain the clearest visualisation of radiopharmaceutical uptake.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant is willing and able to give informed consent for participation in the study;
  • Male or Female, aged 18 years or above;
  • Be able to understand the study, willing to co-operate with the study procedures and able to attend the study assessment;
  • Have been administered a radiopharmaceutical as part of a diagnostic test.

Exclusion Criteria:

  • Female participants who are pregnant, lactating or planning pregnancy during the course of the study;
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study;
  • Patients who have had a nuclear medicine procedure with administration of a radiopharmaceutical within 72 hours prior to the procedure.
  • Patients who do not speak or understand English (since no translator will be available).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03920371


Locations
Layout table for location information
United Kingdom
University of Leicester
Leicester, United Kingdom, LE1 7RH
Sponsors and Collaborators
University of Leicester
Nottingham University Hospitals NHS Trust
University of Nottingham
Investigators
Layout table for investigator information
Study Director: John E Lees, PhD University of Leicester
Publications:
Layout table for additonal information
Responsible Party: University of Leicester
ClinicalTrials.gov Identifier: NCT03920371    
Other Study ID Numbers: 0591
First Posted: April 18, 2019    Key Record Dates
Last Update Posted: April 18, 2019
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Leicester:
small field of view
hybrid compact gamma camera
handheld gamma camera